May 10, 2005: Dublin, Ireland & Prague, Czech Republic
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the
Company"), (AIM:AP.L), the healthcare technology
company focussed on the consumer woundcare, oral
care and coronary health markets, today announces
the signing of a technology and product development
agreement with nanofibre technology specialists ELMARCO
s.r.o. (“Elmarco”) of the Czech Republic for the
development of a next generation delivery platform
for Alltracel's m•doc™ technology.
Elmarco ( www.elmarco.cz/en_profil.php )
is a specialist R&D and manufacturing company
specialising in advanced manufacturing for the semi-conductor
components industry as well as equipment for industrial
production of nanofibrous non-woven materials.
Together with the Textiles Faculty of the Technical
University of Liberic, Elmarco have developed a novel,
proprietary & patented process for spinning polymers
into nano-scale fibres for a range of industrial,
chemical, micro-electronic and bio-medical applications.
Over the past few months m•doc™ based nanofibre
woundcare prototypes have been developed and are
now at an advanced stage of technical evaluation.
Alltracel's CEO Tony Richardson commented
" Alltracel has always
been committed to innovation in our markets and we
are particularly excited by the prospects for m•doc™ based
nanofibrous advanced woundcare delivery systems.
Although at an early stage of development nanofibre technology is showing market
transforming potential in a number of our markets and we are delighted to have
formalised our partnership with Elmarco and the nanofibre technology team at
the Technical University of Liberic.
We are now focussed on jointly reviewing a range of patent protected potential
applications for m•doc™ based nanofibre solutions, initially for the advanced
woundcare and surgical markets and bringing these innovations to market via
our network of existing and new commercial partners.”
Alltracel (AIM: AP.L) ( www.alltracel.com )
Alltracel Pharmaceuticals Plc is a Healthcare Technology
Company focussed on the Consumer Woundcare, Oral-Care
and Coronary Health markets.
With corporate headquarters in Dublin, Ireland;
Alltracel has a commercial office in London, England;
R&D subsidiary in the Czech Republic and manufacturing
facilities in Shenzhen, China
Alltracel was founded in 1996 and listed on London's
Alternative Investment Market in July 2001.
m•doc™ (Micro Dispersed Oxidized Cellulose; ( www.m-doc.com ))
is the end product of Alltracel's patented process and is currently targeting
two major markets.
* In the Consumer HealthCare market this process
applied to cotton in the form of raw cellulose is
proven as an effective and efficient haemostatic
(blood-stopping) agent. Here m•doc™ is currently
being marketed as the leading stops bleeding ingredient
brand within recognized wound care, oral care and
relevant first aid brands worldwide.
* In the Coronary Health market, EU based pre-clinical
and patient studies have demonstrated the m•doc™ technology
platform success in lowering cholesterol and have
indicated longer term coronary health benefits. In
addition pre-clinical work showed significant indications
that the m.doc™ coronary health benefits are additive
in nature, to both statins and sterols. Further efficacy,
dosage and timing/phasing studies to determine optimum
delivery systems, formats and combinations in both
the nutraceutical and pharmaceutical markets are
underway. Development discussions with potential
partners in the nutraceutical and pharmaceutical
sectors in both the EU and North America have commenced.
blotters™ is Alltracel's branded blood stopping
thin film technology for the consumer first aid and
grooming markets. The blotters™ are small, thin,
film strips (similar to breath freshener strips)
impregnated with m•doc™ - Alltracel's unique blood
stopping ingredient and are packed in a convenient
pocket-sized plastic dispenser. When placed on minor
cuts e.g. shaving nicks m•doc™ is released on contact
with the blood, forming a soft gel-like layer over
the wound to stop the bleeding fast.
SEAL•ON™ ( www.seal-on.com )
is the world's first first-aid treatment brand featuring
stops bleeding m•doc™ as standard. The SEAL-ON™ range
features seven different product delivery systems – sprays,
nasal plugs, patches, powder, plasters, dressings
and blotters™ -- each designed for specific usage
occasions and all containing the stops-bleeding m•doc™ ingredient
brand. m•doc™, blotters™, SEAL•ON™ are all trademarks
of Alltracel Pharmaceuticals PLC.
For Further Information Contact:
Dublin: Denise Cronin
Alltracel: +353 1 235 2162
London: Deborah Scott/Davina Langdale
Financial Dynamics: +44 0207 831 3113
New York: Sean Leous
Financial Dynamics: +1 212 850 5626